An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy

被引：2

作者：

Rudelli, G

Annemans, L

Spiesser, J

Novelli, M

Walker, A

Gabriel, S

机构：

[1] Sanofi Synthelabo, Milan, Italy

[2] HEDM, Meise, Belgium

[3] Sanofi Synthelabo Rech, Bagneux, France

[4] Bristol Myers Squibb, Rome, Italy

[5] Bristol Myers Squibb, Rueil Malmaison, France

来源：

VALUE IN HEALTH | 2004年 / 7卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)65788-9

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：686 / 687

页数：2

共 50 条

[1] An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients
Annemans, L
Gabriel, S
Speisser, J
Vranckx, K
De Knock, M
Carita, P
[J]. VALUE IN HEALTH, 2003, 6 (06) : 621 - 622
[2] An economic evaluation of clopidogrel in secondary prevention of ischemic events: High risk populations
Levy, E
Gabriel, S
Carita, P
Dinet, J
[J]. VALUE IN HEALTH, 2002, 5 (06) : 477 - 478
[3] Economic evaluation of clopidogrel in secondary prevention of atherothrombotic events in Hungary
Borsos, K
Nagy, J
Belicza, E
Spiesser, J
Gabriel, S
Blaskó, G
[J]. VALUE IN HEALTH, 2003, 6 (06) : 654 - 654
[4] Secondary Prevention Clopidogrel and Aspirin vs. Aspirin for Early Prophylaxis
Diener, H. C.
[J]. AKTUELLE NEUROLOGIE, 2013, 40 (10) : E55 - E55
[5] Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Bhatt, DL
Topol, EJ
[J]. AMERICAN HEART JOURNAL, 2004, 148 (02) : 263 - 268
[6] Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events
Donadini, Marco P.
Bellesini, Marta
Squizzato, Alessandro
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (06): : 593 - 594
[7] Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA
Gratsiansky, N. A.
[J]. KARDIOLOGIYA, 2006, 46 (05) : 73 - 75
[8] Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients
Ellahham, Samer
[J]. SOUTHERN MEDICAL JOURNAL, 2008, 101 (03) : 273 - 283
[9] Cost-effectiveness of clopidogrel plus aspirin vs. aspirin alone for secondary-prevention of cardiovascular events: Results from the CHARISMA trial
Chen, Jersey
Bhatt, Deepak L.
Schneider, Elizabeth
Shi, Chunxue
Caro, Jaime
Proskorovsky, Irina
Hacke, Werner
Fox, Keith A.
Cohen, David J.
[J]. CIRCULATION, 2006, 114 (18) : 826 - 826
[10] A Comparison of Aspirin and Clopidogrel With or Without Proton Pump Inhibitors for the Secondary Prevention of Cardiovascular Events in Patients at High Risk for Gastrointestinal Bleeding
Hsiao, Fei-Yuan
Tsai, Yi-Wen
Huang, Weng-Foung
Wen, Yu-Wen
Chen, Pei-Fen
Chang, Po-Yin
Kuo, Ken N.
[J]. CLINICAL THERAPEUTICS, 2009, 31 (09) : 2038 - 2047

← 1 2 3 4 5 →